We are proud to participate in clinical research studies with the goal of advancing the field of reproductive medicine, improving success rates, and delivering on a higher standard of patient care.
We are actively seeking participants in several research studies, and we invite you to explore the studies below. If you qualify for and are interested in participating in any of the below studies, please contact our Clinical Research Coordinator, Brianna Brigham at [email protected]
This clinical research study will investigate the efficacy of subcutaneous progesterone injections to replace intramuscular progesterone injections and/or vaginal suppositories as the primary method of luteal support following a frozen embryo transfer. Subcutaneous injections may be preferable because they are less painful, less expensive, and less cumbersome than the existing methods. Subcutaneous injections may improve overall quality of experience for patients following an FET.
Women planning Frozen Embryo Transfer with a genetically tested, euploid embryo made from their own egg
• At least one embryo frozen at the blastocyst stage (day 5-7) that meet Spring’s grading criteria
• Age 35-42
• Regular ovulatory menstrual cycles, defined as between 24 – 38 days in length
• BMI (Body Mass Index) < 38
• Less than 3 previous consecutive euploid blastocyst transfers without a live birth
• Procedure documenting a normal uterine cavity within the last 12 months
• Use of donor eggs or planned use of gestational carrier
• Two or more failed clinical pregnancies
• Participants will be randomly assigned to one of two treatment methods to support implantation and early pregnancy following FET
• Participation inclusive of 8 office visits, including screening and embryo transfer
• Reporting pregnancy outcome to Spring Fertility
• Financial compensation will be available for this study’s participants
This study will evaluate the pregnancy outcomes following the transfer of abnormal and mosaic embryos. It is intended for patients who have no chromosomally normal embryos and for whom this may be the last remaining option. As chromosomes decrease in size, especially those chromosomes numbered greater than 15, they have fewer unique regions that can be sampled for aneuploidy in genetic testing, and so it becomes more challenging to make definitive calls on if these chromosomes are “normal”. This study will transfer abnormal and mosaic embryos on the hypothesis that some were determined incorrectly due to analytical error.
• You desire transfer of an abnormal or mosaic embryo following your PGT-A testing o Embryo must meet Spring Fertility’s grading criteria o Spring Fertility must have access to full genetic testing records
• You agree to a multi-specialty counseling session with our psychologist, genetic counselor, and your physician What does the Study Participation Involve?
• Agreeing to report pregnancy outcome to Spring Fertility following delivery
• Donation of any unused abnormal or mosaic embryos